Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings Inc. (NASDAQ: NTHI), a clinical-stage life sciences company focused on central nervous system therapeutics. The company recently announced positive Phase 1/2a results for its lead asset, NEO100, with top-line Phase 2a data expected in mid-2026. The closing and funding of the Quazar Investment is also anticipated in the near term. For more details, visit https://www.newsfilecorp.com/release/193551
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 279982) on January 10, 2026, and is solely responsible for the information contained therein.